Natural and Synthetic Polymers As Inhibitors of Drug Efflux Pumps

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2007 Sep 27

PMID 17896100

Citations 45

Authors

Martin Werle

Affiliations

Soon will be listed here.

Abstract

Inhibition of efflux pumps is an emerging approach in cancer therapy and drug delivery. Since it has been discovered that polymeric pharmaceutical excipients such as Tweens or Pluronics can inhibit efflux pumps, various other polymers have been investigated regarding their potential efflux pump inhibitory activity. Among them are polysaccharides, polyethylene glycols and derivatives, amphiphilic block copolymers, dendrimers and thiolated polymers. In the current review article, natural and synthetic polymers that are capable of inhibiting efflux pumps as well as their application in cancer therapy and drug delivery are discussed.

Citing Articles

Nanoparticles in the battle against Candida auris biofilms: current advances and future prospects.

Fayed B Drug Deliv Transl Res. 2024; .

PMID: 39589626 DOI: 10.1007/s13346-024-01749-w.

"Enhancing Oral Drug Absorption: Overcoming Physiological and Pharmaceutical Barriers for Improved Bioavailability".

Maurya R, Vikal A, Patel P, Narang R, Kurmi B AAPS PharmSciTech. 2024; 25(7):228.

PMID: 39354282 DOI: 10.1208/s12249-024-02940-5.

Lipid-Based Self-Microemulsion of Niclosamide Achieved Enhanced Oral Delivery and Anti-Tumor Efficacy in Orthotopic Patient-Derived Xenograft of Hepatocellular Carcinoma in Mice.

Liu Y, Guerrero D, Lechuga-Ballesteros D, Tan M, Ahmad F, Aleiwi B Int J Nanomedicine. 2024; 19:2639-2653.

PMID: 38500681 PMC: 10946447. DOI: 10.2147/IJN.S442143.

Third-Generation Solid Dispersion Through Lyophilization Enhanced Oral Bioavailability of Resveratrol.

Almeida H, Ferreira B, Fernandes-Lopes C, Araujo F, Bonifacio M, Vasconcelos T ACS Pharmacol Transl Sci. 2024; 7(3):888-898.

PMID: 38481698 PMC: 10928883. DOI: 10.1021/acsptsci.4c00029.

Recent Advancements in the Development of Nanocarriers for Mucosal Drug Delivery Systems to Control Oral Absorption.

Sato H, Yamada K, Miyake M, Onoue S Pharmaceutics. 2023; 15(12).

PMID: 38140049 PMC: 10747340. DOI: 10.3390/pharmaceutics15122708.

References

Lugo M, Sharom F . Interaction of LDS-751 with P-glycoprotein and mapping of the location of the R drug binding site. Biochemistry. 2005; 44(2):643-55. DOI: 10.1021/bi0485326. View

Batrakova E, Li S, Li Y, Alakhov V, Kabanov A . Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res. 2005; 21(12):2226-33. PMC: 2677181. DOI: 10.1007/s11095-004-7675-5. View

Gillies E, Frechet J . Dendrimers and dendritic polymers in drug delivery. Drug Discov Today. 2005; 10(1):35-43. DOI: 10.1016/S1359-6446(04)03276-3. View

Varma M, Panchagnula R . Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo. Eur J Pharm Sci. 2005; 25(4-5):445-53. DOI: 10.1016/j.ejps.2005.04.003. View

Venditto V, Regino C, Brechbiel M . PAMAM dendrimer based macromolecules as improved contrast agents. Mol Pharm. 2005; 2(4):302-11. DOI: 10.1021/mp050019e. View

Bernkop-Schnurch A . Thiomers: a new generation of mucoadhesive polymers. Adv Drug Deliv Rev. 2005; 57(11):1569-82. DOI: 10.1016/j.addr.2005.07.002. View

Galindo-Rodriguez S, Allemann E, Fessi H, Doelker E . Polymeric nanoparticles for oral delivery of drugs and vaccines: a critical evaluation of in vivo studies. Crit Rev Ther Drug Carrier Syst. 2005; 22(5):419-64. DOI: 10.1615/critrevtherdrugcarriersyst.v22.i5.10. View

Dufes C, Uchegbu I, Schatzlein A . Dendrimers in gene delivery. Adv Drug Deliv Rev. 2005; 57(15):2177-202. DOI: 10.1016/j.addr.2005.09.017. View

Liu C, Wu J, Shi B, Zhang Y, Gao T, Pei Y . Enhancing the bioavailability of cyclosporine a using solid dispersion containing polyoxyethylene (40) stearate. Drug Dev Ind Pharm. 2006; 32(1):115-23. DOI: 10.1080/03639040500388573. View

10.

Werle M, Hoffer M . Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J Control Release. 2005; 111(1-2):41-6. DOI: 10.1016/j.jconrel.2005.11.011. View

11.

Collnot E, Baldes C, Wempe M, Hyatt J, Navarro L, Edgar K . Influence of vitamin E TPGS poly(ethylene glycol) chain length on apical efflux transporters in Caco-2 cell monolayers. J Control Release. 2006; 111(1-2):35-40. DOI: 10.1016/j.jconrel.2005.11.005. View

12.

Shen Q, Lin Y, Handa T, Doi M, Sugie M, Wakayama K . Modulation of intestinal P-glycoprotein function by polyethylene glycols and their derivatives by in vitro transport and in situ absorption studies. Int J Pharm. 2006; 313(1-2):49-56. DOI: 10.1016/j.ijpharm.2006.01.020. View

13.

Shilling R, Venter H, Velamakanni S, Bapna A, Woebking B, Shahi S . New light on multidrug binding by an ATP-binding-cassette transporter. Trends Pharmacol Sci. 2006; 27(4):195-203. DOI: 10.1016/j.tips.2006.02.008. View

14.

Foger F, Schmitz T, Bernkop-Schnurch A . In vivo evaluation of an oral delivery system for P-gp substrates based on thiolated chitosan. Biomaterials. 2006; 27(23):4250-5. DOI: 10.1016/j.biomaterials.2006.03.033. View

15.

Raub T . P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharm. 2006; 3(1):3-25. DOI: 10.1021/mp0500871. View

16.

Crivori P, Reinach B, Pezzetta D, Poggesi I . Computational models for identifying potential P-glycoprotein substrates and inhibitors. Mol Pharm. 2006; 3(1):33-44. DOI: 10.1021/mp050071a. View

17.

Choudhuri S, Klaassen C . Structure, function, expression, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol. 2006; 25(4):231-59. DOI: 10.1080/10915810600746023. View

18.

Varma M, Perumal O, Panchagnula R . Functional role of P-glycoprotein in limiting peroral drug absorption: optimizing drug delivery. Curr Opin Chem Biol. 2006; 10(4):367-73. DOI: 10.1016/j.cbpa.2006.06.015. View

19.

Foger F, Hoyer H, Kafedjiiski K, Thaurer M, Bernkop-Schnurch A . In vivo comparison of various polymeric and low molecular mass inhibitors of intestinal P-glycoprotein. Biomaterials. 2006; 27(34):5855-60. DOI: 10.1016/j.biomaterials.2006.08.004. View

20.

Girardin F . Membrane transporter proteins: a challenge for CNS drug development. Dialogues Clin Neurosci. 2006; 8(3):311-21. PMC: 3181821. View